疑似氯氮平所致严重中性粒细胞减少96例评估
该研究基于南伦敦与莫兹利NHS信托基金会的匿名病例登记数据,提取了96例氯氮平使用期间连续两次中性粒细胞计数低于1.5×10^9/L的病例,由临床医生小组独立评估。结果显示,仅9例(9.4%)被判定为明确由氯氮平引起,11例(11.5%)很可能由氯氮平引起,合计18例(18.8%)应永久禁用氯氮平;近80%的病例中氯氮平并非中性粒细胞减少的明确原因。结论提示,基于阈值的监测系统可能因缺乏特异性而导致不必要的氯氮平停用。
要点
- 96例连续两次中性粒细胞低于1.5×10^9/L的病例中,仅18.8%被判定为明确或很可能由氯氮平引起。
- 近80%的严重中性粒细胞减少病例中,氯氮平并非明确原因,包括良性种族性中性粒细胞减少、化疗、感染和实验室误差。
- 基于阈值的监测系统可能因特异性不足而导致不必要的氯氮平停用。
核心结论
- 大多数因严重中性粒细胞减少而停用氯氮平的病例可能并非由氯氮平引起。
- 基于阈值的监测系统缺乏对氯氮平相关血液病的特异性,导致不必要的停药。
研究设计与样本
- 研究使用南伦敦与莫兹利NHS信托基金会匿名病例登记库(Clinical Record Interactive Search)的数据。
- 提取氯氮平使用期间连续两次中性粒细胞计数低于1.5×10^9/L的病例,由临床医生小组独立评估因果关系、生命风险及能否再次挑战氯氮平。
主要发现
- 共纳入96例连续两次中性粒细胞计数低于1.5×10^9/L的病例。
- 评估小组判定9例(9.4%)明确由氯氮平引起,11例(11.5%)很可能由氯氮平引起。
- 合计18例(18.8%)应永久禁用氯氮平,均来自明确或很可能由氯氮平引起的20例病例。
- 其余76例中,60例原因未确定,11例为良性种族性中性粒细胞减少,2例为癌症化疗,2例为感染,1例为实验室误差。
- 近80%的病例中,氯氮平并非所观察到的中性粒细胞减少的明确原因。
关键数值与推荐
- 严重中性粒细胞减少定义为连续两次中性粒细胞计数低于1.5×10^9/L。
- 评估小组判定明确由氯氮平引起9例(9.4%),很可能由氯氮平引起11例(11.5%),合计18例(18.8%)应永久禁用氯氮平。
- 其余76例中,60例原因未确定,11例为良性种族性中性粒细胞减少,2例为癌症化疗,2例为感染,1例为实验室误差。
临床怎么用
- 临床遇到氯氮平使用期间出现严重中性粒细胞减少时,应综合评估其他可能原因,避免仅凭阈值自动永久停用氯氮平。
- 对于明确或很可能由氯氮平引起的严重中性粒细胞减少患者,应永久禁用氯氮平。
- 对原因未确定或非氯氮平所致的中性粒细胞减少,可考虑在严密监测下评估再次挑战氯氮平的可能性。
局限性
- 研究为回顾性病例登记分析,因果关系评估依赖临床医生小组判断。
- 部分病例原因未确定,可能存在未测量的混杂因素。
- 结论基于单中心数据,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clozapine remains underused despite its unparalleled efficacy in treatment-refractory schizophrenia. One of the reasons for its underuse is the fear of severe neutropenia and its consequences. AIMS: To scrutinise the association between severe neutropenia and clozapine in a cohort of patients clinically diagnosed with clozapine-induced severe neutropenia. METHOD: We used data from the South London and Maudsley National Health Service Foundation Trust's anonymised case register, known as the Clinical Record Interactive Search. We extracted details of cases where clozapine use was associated with two consecutive neutrophil counts below 1.5 × 109/L. A panel of clinicians independently assessed each case. Agreement was reached on which cases clozapine was the likely or definite cause of the severe neutropenia, the risk to life and whether or not rechallenge with clozapine could be attempted. RESULTS: There were 96 cases where two consecutive neutrophil counts below 1.5 × 109/L were registered. The panel judged that 9 (9.4%) were definitely caused by clozapine and a further 11 (11.5%) were probably caused by clozapine. Overall, 18 (18.8%) patients should be precluded from ever receiving clozapine again according to the panel (all from the 20 cases where clozapine was the definite or probable cause). Of the remaining 76 cases of severe neutropenia the cause could not be determined in 60 cases, but in 11 cases the cause was benign ethnic neutropenia, in 2 others the cause was cancer chemotherapy, in 2 it was infections and in 1 it was laboratory error. In almost 80% of cases, clozapine was not the clear cause of the neutropenia observed. CONCLUSIONS: The large majority of severe neutropenia episodes mandating cessation of clozapine may not be caused by clozapine. Threshold-based monitoring systems cause unnecessary stopping of clozapine because they lack the necessary specificity for clozapine-related blood disorders.
引用
- Wallman P, Govind R, Casetta C, et al. Evaluation of 96 cases of apparent clozapine-induced severe neutropenia. Br J Psychiatry. 2025. PMID: 41059642. doi:10.1192/bjp.2025.10423
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。